戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 as the treatment of choice for uncomplicated travelers' diarrhea.
2 received an antibiotic for self-treatment of travelers' diarrhea.
3 imin provided 72% and 77% protection against travelers' diarrhea and antibiotic-treated travelers' di
4  appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatment of portal systemi
5  Rifaximin is effective for the treatment of travelers' diarrhea and can be considered as the treatme
6 uals susceptible to Escherichia coli-induced travelers' diarrhea and in tear fluid derived from viral
7 t commonly isolated pathogen responsible for travelers' diarrhea and the cause of up to 650 million c
8 strongyloidiasis, and filariasis) as well as travelers' diarrhea and vaccination for SOT candidates a
9    NoVs were identified in 10.2% of cases of travelers' diarrhea and, overall, was the second most co
10 ed in the United States for the treatment of travelers' diarrhea caused by noninvasive diarrheagenic
11                                              Travelers' diarrhea causes substantial morbidity and pos
12                                              Travelers' diarrhea developed in 14.74% of participants
13                                              Travelers' diarrhea exacerbates the risk of acquiring mu
14                       Large field studies of travelers' diarrhea for multiple destinations are limite
15 i (ETEC) is a leading cause of childhood and travelers' diarrhea, for which an effective vaccine is n
16 is responsible for causing severe infant and travelers' diarrhea, gastroenteritis and hemolytic uremi
17  agent, was demonstrated in the treatment of travelers diarrhea in Mexico.
18                   Rifaximin safely prevented travelers' diarrhea in Mexico, where most cases are caus
19              NoVs are important pathogens of travelers' diarrhea in multiple regions of the world.
20 tile diarrhea in the developing world and of travelers' diarrhea in visitors to these areas from indu
21                    Recommended treatment for travelers' diarrhea includes the combination of an antib
22                                When invasive travelers' diarrhea pathogens are suspected, an alternat
23 t travelers' diarrhea and antibiotic-treated travelers' diarrhea, respectively (P < 0.001 for both),
24            In the groups that did not report travelers' diarrhea, rifaximin significantly reduced the
25 ons of Enterobacteriaceae infection included travelers' diarrhea (TD) (75/90 subjects) and urinary tr
26             Geographic region, occurrence of travelers' diarrhea (TD), age, and use of antimicrobial
27 onducted for the treatment and prevention of travelers' diarrhea, the treatment of portal systemic en
28  enterotoxigenic Escherichia coli (ETEC) and travelers' diarrhea was examined in a high-risk area in
29                           Rifaximin prevents travelers' diarrhea with minimal changes in fecal flora,